Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Pardes Biosciences, Inc. ( the “Company”) for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Thomas G. Wiggans, Chief Executive Officer of the Company, and Heidi Henson, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:
Date: November 7, 2022
By: |
| /s/ Thomas G. Wiggans |
|
| Thomas G. Wiggans |
|
| Chief Executive Officer |
|
| (Principal Executive Officer) |
Date: November 7, 2022
By: |
| /s/ Heidi Henson |
|
| Heidi Henson |
|
| Chief Financial Officer |
|
| (Principal Financial Officer) |